Evidence map›Paper›PMID 26283207›Full record

ArticleSurgery2015

Resveratrol decreases nitric oxide production by hepatocytes during inflammation.

Charles W Kimbrough, Jaganathan Lakshmanan, Paul J Matheson, Matthew Woeste, Andrea Gentile, Matthew V Benns, Baochun Zhang, Jason W Smith, Brian G Harbrecht

Abstract readEvaluation Study
In one paragraph

Article in Surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. AqueousJournal of diabetes and metabolic disorders · 2020
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Charles W KimbroughThe Hiram C. Polk Jr., MD Department of Surgery and Price Institute of Surgical Research, University of Louisville School of Medicine, Louisville, KY.
Jaganathan LakshmananThe Hiram C. Polk Jr., MD Department of Surgery and Price Institute of Surgical Research, University of Louisville School of Medicine, Louisville, KY.
Paul J MathesonThe Hiram C. Polk Jr., MD Department of Surgery and Price Institute of Surgical Research, University of Louisville School of Medicine, Louisville, KY.
Matthew WoesteThe Hiram C. Polk Jr., MD Department of Surgery and Price Institute of Surgical Research, University of Louisville School of Medicine, Louisville, KY.
Andrea GentileThe Hiram C. Polk Jr., MD Department of Surgery and Price Institute of Surgical Research, University of Louisville School of Medicine, Louisville, KY.
Matthew V BennsThe Hiram C. Polk Jr., MD Department of Surgery and Price Institute of Surgical Research, University of Louisville School of Medicine, Louisville, KY.
Baochun ZhangThe Hiram C. Polk Jr., MD Department of Surgery and Price Institute of Surgical Research, University of Louisville School of Medicine, Louisville, KY.
Jason W SmithThe Hiram C. Polk Jr., MD Department of Surgery and Price Institute of Surgical Research, University of Louisville School of Medicine, Louisville, KY.
Brian G HarbrechtThe Hiram C. Polk Jr., MD Department of Surgery and Price Institute of Surgical Research, University of Louisville School of Medicine, Louisville, KY. Electronic address: briang.harbrecht@louisville.edu.
Rice Institute · US

Funding

Hepatocyte Nitric Oxide Synthase Regulation by Glucagon and InsulinR01DK055664 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HARBRECHT, BRIAN G. · 2001 to 2012
$2.6M
Summer Endocrine Research Training ProgramT35DK072923 · NIDDK · UNIVERSITY OF LOUISVILLE · PI KLINGE, CAROLYN M. · 2006 to 2025
$719k
ROCHESTER TRAINING FOR ORAL HEALTH CLINICAL TRIALST35DE007293 · NIDCR · UNIVERSITY OF ROCHESTER · PI MEYEROWITZ, CYRIL · 1996 to 2001
$56k
NIDCR NIH HHS T35 DE007293NIDDK NIH HHS DK-55664NIDDK NIH HHS R01 DK055664NIDDK NIH HHS T35 DK072923NIDDK NIH HHS T35 DK07293
6 · The paper itself

Abstract

introductionThe production of excessive amounts of nitric oxide (NO) through inducible nitric oxide synthase (iNOS) contributes to organ injury, inflammation, and mortality after shock. Resveratrol (RSV) is a natural polyphenol that decreases shock-induced hepatic injury and inflammation. We hypothesized that RSV would mediate these effects by decreasing hepatocyte iNOS production.

methodsRat hepatocytes were isolated, cultured with varying concentrations of RSV, and then stimulated to induce iNOS with interleukin-1 and interferon. Induction of iNOS protein was measured by Western blot, iNOS mRNA by polymerase chain reaction, and NO production was measured by culture supernatant nitrite. Activation of intracellular signaling pathways involving Akt, c-Jun N-terminal kinase (JNK), and nuclear factor κB (NF-κB) were measured by Western blot using isoform-specific antibodies.

resultsRSV decreased the expression of iNOS mRNA, protein, and supernatant nitrite in a dose-dependent manner. Our previous work demonstrated that Akt and JNK both inhibit hepatic iNOS production, whereas NF-κB increases iNOS expression. Analysis of signaling pathways in this study demonstrated that RSV increased JNK phosphorylation but decreased Akt phosphorylation and increased NF-κB activation.

conclusionRSV decreases cytokine-induced hepatocyte iNOS expression, possibly through up-regulation of the JNK signaling pathway. RSV merits further investigation to determine its mechanism as a compound that can decrease inflammation after shock.

Indexed as

AnimalsAnti-Inflammatory Agents, Non-SteroidalBiomarkersBlotting, WesternCells, CulturedCytokinesDose-Response Relationship, DrugHepatocytesInflammationMaleNitric OxideNitric Oxide Synthase Type IIPolymerase Chain ReactionRatsRats, Sprague-DawleyResveratrolAnti-Inflammatory Agents, Non-SteroidalBiomarkersCytokinesNitric OxideNitric Oxide Synthase Type IIResveratrolStilbenes

Identifiers

PMID26283207
PMCPMC4567468
OpenAlexW2170443986

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.